BVS vs MEDP: fair value comparison
Bioventus Inc. and Medpace Holdings, Inc. · Updated 2026-08-31
BVS currently screens as fairly valued while MEDP screens as overvalued. Within Healthcare, BVS currently sits closer to the top of our discount ranking. MEDP carries the stronger quality grade.
| BVS | MEDP | |
|---|---|---|
| Verdict | Fairly valued | Overvalued |
| Last price | $13.47 | $573.29 |
| 12-month range | $6.56–$13.47 | $417.54–$594.02 |
| Sector rank | #86 of 113 Healthcare | #90 of 113 Healthcare |
| Quality grade | D | C |
| Momentum grade | B | — |
| Leverage | Moderate | Low |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BVS fair value analysis · MEDP fair value analysis